written on 03.06.2014
Tags:
,

Study: Subbing Avastin for Lucentis could save U.S. $3B on eye treatment

TAGS: ,

Doctors have long repurposed Roche's Avastin for the eye in place of using the company's pricier Lucentis to save money. Now, a study says the U.S. could save almost $3 billion a year if Medicare patients received the cheaper drug–a prospect Roche isn't so keen on.

Latest Report